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1. Introduction 
Widely used in surgical anesthesia, obstetric analgesia, –postoperative pain control and in 
the treatment of chronic pain, epidural techniques are contraindicated in such conditions as 
coagulopathy and other bleeding diathesis, patient refusal, hemodynamic instability, 
increased intracranial pressure and local or systemic infection.  
Contraindications for epidural analgesia are patient reluctance, bleeding diathesis, 
hemodynamic instability, increased intracranial pressure and local or systemic infection. 
Contraindications are listed in Table 1. 
Coagulation defects may be inherited or acquired (Table 2). 
2. Contraindications - Hemorrhage and coagulopathy, and patient refusal 
2.1 Coagulation and regulation of thrombin generation  
Blood coagulation is a physiologic defense mechanism which develops as a response to a 
vascular damage and protects the integrity of the circulatory system. A hemostatic response 
to a trauma is a series of complex and interrelated events that necessitate interaction of the 
vessel wall, plasma proteins and platelets (Colman et al., 2001). This interaction results in 
one of the three outcomes: Hemorrhage, an appropriate hemostasis or a pathologic 
thrombosis (Hess & Lawson, 2006). 
The cell-based coagulation method is frequently used today in understanding hemostasis. 
This model is divided into initiation, amplification and propagation phases (Hoffman & 
Monroe, 2001; Tanaka et al., 2009). 
In the initiation phase, the surface of endothelium is activated by molecular or physical 
(traumatic or surgical) signals and it becomes the focal point of the procoagulant activity. 
The endogenous heparin molecule is removed from the surface of endothelium and the 
anticoagulant molecules become subject to thrombomoduline and antithrombin down 
regulation. A tissue factor is exposed to and the composition of endothelium surface 
phospholipids changes. To initiate formation of a clot, the tissue factor (TF) recruits 
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coagulation zymogen factor VII. Activated factor VII (VIIa) converts factor IX and factor X 
into their active enzyme forms. Activated factor X(Xa) then converts prothrombin (fII) into 
thrombin (fIIa) and factor V (fV) into factor Va (fVa) (Adams et al., 2007). Thrombin so 
formed and fibrin which is formed from fibrinogen with the effect of thrombin are in very 
small amounts. 
 
  Coagulopathy and other bleeding diathesis  
  Patient refusal 
  Hemodynamic instability  
  Increased intracranial pressure  
  Local or systemic infection  
  Pre-existing neurological disorders  
Table 1. Epidural blockage contraindications 
 
Inherited 
Hemophilia A and Hemophilia B 
von Willebrand disease 
Factor V deficiency 
Inherited disorders of platelet disfunctions 
Inherited hemorrhagic telangiectasia 
Inherited thrombophilia 
Acquired 
Vitamin K deficiency 
Drug-associated hemorrhage 
Drug-associated hemorrhage 
Disseminated intravascular coagulation 
The Coagulopathy of Massive Trauma 
Idiopathic thrombocytopenic purpura  
Table 2. Classification of Coagulation Defects 
In the amplification phase of thrombus, activated platelets bind to endothelium, activate 
factors V, XI and VIII and increase formation of thrombin through a positive feedback cycle 
(Adams et al., 2007; Hoffman & Monroe, 2001; Tanaka, 2009). Thrombocytes play a major 
role in localized clotting reactions in the trauma area. Thromobcytes bind and adhere to von 
Willebrand factor (vWF), thrombin, platelet receptors and subendothelial collagen in the 
trauma area and they form an aggregation. In this way, the surface for generation of 
required thrombin is formed for an effective hemostasis (Falati et al., 2002). As a result of the 
activation of platelets, cofactors Va and VIIIa quickly get localized on the surface of 
thrombocytes (Monroe et al., 1994). Factor Va accelerates and intensifies the activation of 
factor Xa. Factor VIIIa accelerates the binding of factor XIa to IXa (Adams et al., 2006) and 
enables continuation of procoagulant responses (Gailani & Broze, 1991). 
In the propagation phase, fibrin polymerization and fibrin clotting occur. Thrombin first 
cleaves fibrinopeptide A and fibrinopeptide B particles from fibrinogen molecule and 
generates fibrin monomers and then fibrin polymers when these monomers aggregate. 
Thrombin also activates factor XIII to enable formation of cross-links among fibrin polymers 
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and a firm fibrin clot (Hornyak & Shafer, 1992). A large amount of thrombin generated on 
the surface of thrombocyte is responsible for stabilization of the clot rather than supporting 
the polymerized fibrin (Hoffman & Monroe, 2007). 
The coagulation cascade should be controlled and strictly monitored to confine it only in the 
area required. Many coagulation factors are serine protease and the coagulation process is 
regulated by serine protease inhibitors protein C and S, tissue factor pathway inhibitor 
(TFPI) and antithrombin. These agents inhibit clotting and formation of localized clot in the 
injured area. The fibrinolytic system in turn is activated and plays a role in dissolving the 
clot, healing the injury and reforming the tissue ( Levy et al., 2010).  
As a result, the competition of the procoagulant, anticoagulant, fibrinolytic and 
antifibrinolytic ways are regulated and remain in balance in human physiology. However, if 
a surgical stress, trauma or disease pushes any of these ways of competition out of balance, 
then it results in a pathologic condition that leads to either a hemorrhage or thrombosis 
(Hess & Lawson, 2006).  
 
Fig. 1. Model of coagulation and regulation of thrombin generation. 
2.2 Preoperative coagulation evaluation 
The screening tests to determine bleeding risk in patients is ideally carried out in the 
preoperative period. Identification of hemostatic defects in this way helps in the 
preoperative period in the management of unpreventable bleeding. A history or a family 
history of bleeding in anamnesis increases the risk. The history of drug usage and the effect 
of used medicament to the coagulation cascade should be questioned. 
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Petechia, purpura, bleeding of nose or gums, hematuria, melena and other signs of bleeding 
should be noted as risk-increasing factors (Adams et al., 2007). Especially petechia 
(capillary) and purpura, which are physical characteristics of bleeding, as well as hematoma 
and ecchymose resulting from a large blood vessel bleeding should be well-explained. In 
detecting an inherited coagulopathy, presence of bleeding without any history of a disease 
or anticoagulant drug usage in the patient directly attracts the attention to an inherited 
defect.   
Laboratory tests should be conducted in relation to the patient’s clinical condition and 
history of bleeding and the type of planned surgery (Table 3). 
Although preoperative scanning tests are not required in healthy individuals, neuraxial 
blockade, coagulation examinations and platelet counts should be conducted in cases in 
which clinical history indicates a probability of hemorrhage (Morgan et al., 2008). 
 
Laboratory tests                            Normal values                            
Prothrombin time                            10-14 sec 
Partial thromboplastin time   22-35 sec 
International normalized ratio (INR) 0.80-1.30 
Platelet Count 150.000-450.000/µL 
Bleeding time 3-8 min 
Thrombin time 9-25 sec 
Fibrinogen assay  
   Healthy individuals                       200–400 mg/dL 
   With severe illness                        400–800 mg/dL 
Specific factors and inhibition levels  
Table 3. Laboratory tests and normal values   
No testing is required in patients who have no history of bleeding and will undergo a minor 
surgery. In patients who have no history of bleeding but will undergo a major surgery, 
counts of partial thromboplastin time (PTT) and trombocyte is recommended. In patients 
with hemostatic disorders, the number of trombocytes, bleeding time, PTT and 
thromboplastin time should be measured (Adams et al., 2007). 
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are the most 
widely used tests in screening coagulation disorders. PT is affected by reductions of Factors 
VII, X, V, and prothrombin such as occur with vitamin K antagonist therapy (Levy et al., 
2008) or severe liver disease (Tripodi et al., 2007). aPTT is sensitive to gross reductions of 
Factors V, VIII, IX, XI, XII, and to a lesser extent, prothrombin (Tanaka et al., 2009). These 
screening coagulation tests are abnormal when there is a deficiency of one or more of the 
soluble coagulation factors (Hoffman & Monroe, 2007). 
A consensus could not be reached about the minimum hemostatic condition required by 
regional techniques. One of the most common views is that if there is a thrombcyte function 
as a minimum threshold, then the hemostatic capacity is sufficient. Although a number of 
tests are carried out to assess the thrombocyte function today, it is not possible to arrive at 
definite information about the adequacy of coagulation. In these circumstances, the 
administration of a regional anesthesia and the minimum hemostatic condition that is 
required to apply the anesthesia can be realized if;  
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  the number of functional platelets >80-100 000 µL-1, 
  international normalized ratio (INR) < 1.5,  
  activated prothrombin time (aPTT) <45 sec. 
(Llau et al., 2005; Tyagi & Bhattacharya, 2002; Mentegazziet al., 2005). 
2.3 Coagulation defects 
2.3.1 Inherited coagulation defects 
Inherited coagulation defects generally appear because of the absence or insufficiency of a 
single coagulation factor.  
2.3.1.1 Hemophilia A and hemophilia B 
Hemophilia A and B are X-linked recessively inherited disorders. The incidence of 
hemophilia is 1 in 5000 male births an that of hemophilia B is 1 in 30000 (Tuddenham & 
Cooper, 1994 ). 
Characterized by excessive bleeding in various parts of the body, hemophilia develops due 
to a mutation of factor VIII (Hemophilia A) and factor IX (Hemophilia B) coagulation genes. 
The chance of inheriting a gene defect from a hemophilia carrier is 50%. A patient’s son is 
affected with a chance of 50% at every pregnancy and her daughter, who is also a carrier of 
the disease, is also affected with a chance of 50% (Cahill & Colvin, 1997 ). However, 
hemophilia may also develop in 30% of the cases as a result of a spontaneous mutation 
without any history of hemophilia in the family (Mannucci & Tuddenham, 2001). 
Hemophilia is classified according to the level of the clotting factor. A hundred percent of 
the said factor which is contained in 1 mL of normal plasma is referred to as 1 unit. Normal 
plasma activity is between 5 U.dl-1 and 15 U.dl-1 (50-150%) (DiMichele & Neufeld, 1998). The 
level of normal factor in seriously affected patients is <1%, in moderately affected 1-4% and 
in mildly affected 5-50% (Cahill & Colvin, 1997 ). While those with serious hemophilia are 
susceptible to spontaneous bleeding episodes, the ones with mild hemophilia have bleeding 
after a trauma or surgery (Mannucci & Tuddenham, 2001).  
There are case reports in the literature notifying the occurrence of an epidural hematoma 
following a lumbar puncture in patients who were not known to have hemophilia (Bernhardt 
et al., 2008; Faillace et al., 1989). The use of a regional block in patients with bleeding disorders 
is controversial because of the risk of developing hematoma which leads to epidural or spinal 
bleeding and a permanent neurological damage. However, the use of a regional block is not 
contraindicated when the coagulation tests (platelet quantity, PT, aPTT, INR and fibrinogen) 
are normal and the relevant factor level is >50IU.dl-1 or is raised to >50IU.dl-1 through a 
prophylactic treatment (Lee et al., 2006; Silverman et al., 1993; , Dhar et al., 2003). 
An epidural intervention should be applied with a midline approach by an experienced 
anesthetist (Abramovitz & Beilin, 2003). A mixture of low-dose local anesthetics and 
narcotics should be used to attain analgesia by protecting the motor function (Dhar et al., 
2003). Motor block measurements should be carried out frequently until the catheter is 
removed. If the degree of the motor block is higher than expected and the length of 
anesthesia is prolonged, a magnetic resonance imaging should be made to control 
development of an epidural hematoma.  
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It is important to check the factor levels before the epidural catheter is removed. 
2.3.1.2 von Willebrand disease (vWD) 
Von Willebrand disease (vWD) is an inherited hematologic disorder which involves vWF 
deficiency and is the most prevailing bleeding disorder affecting nearly 1% of the general 
population (Rodeghiero et al., 1987). vWD is divided into three types according to the 
qualitative and quantitative deficiency of the vWF level. The vWF level is decreased in vWD 
Type 1; it is normal in Type 2, but there is a function disorder. The vWF deficiency is serious 
in vWD Type 3. The most common one is Type 1 which constitutes approximately 70% of 
the cases. While vWD Types 1 and 2 are inherited autosomal dominantly, Type 3 is 
inherited autosomal recessively (Lee et al., 2006).  
vWF is necessary for adhesion of platelets to form a platelet clump in an injured 
endothelium. It is also the carrier protein of Factor VIII. When vWF is deficient, the time of 
bleeding is prolonged and patients generally have abnormal bleedings such as epistaxis, 
menorrhagia and postpartum bleeding (Varughese &Cohen, 2007). Tendency to bleeding is 
moderate in vWD Type 1 and 2, but serious in Type 3. Pregnant women with vWD have a 
progressively increasing FVIII coagulation activity (FVIII:C), and vWF antigen (vWF:Ag) 
and vWF activity (vWF:AC) during pregnancy, which all return to the baseline after 
delivery (Greer et al., 1991; Punnonen et al., 1981; Kadir et al., 1998). The increase in the 
variables showing such platelet activity is apparent in pregnant women with vWD Type 1, 
moderate in Type 2 and very little or nil in Type 3. Because of the differences in hemostatic 
responses, the factor levels with plasma vWF:Ag, VWF:AC and FVIII:C should regularly be 
monitored in pregnant women with vWD. 
 When the vWF activity becomes <50 IU.dl-1 during an invasive intervention or a delivery, a 
prophylactic treatment should be initiated using a coagulation factor concentrate with vWF. 
A prophylactic treatment is not necessary at delivery in women with vWD Type 1. 
Treatment becomes necessary in vWD Type 2 if a cesarean section is being carried out or a 
perineal trauma occurred. Women with vWD Type 3 require treatment in all types of 
delivery (Lee et al., 2006). 
The risk of developing a spinal hematoma after an epidural anesthesia is very rare in 
obstetric patients (1:200000). However, this risk increases in patients with serious 
coagulopathy (Moen et al., 2004). Neuraxial interventions are contraindicated in patients 
with vWD whose bleeding disorders are not healed. Although vWD is quite common 
among bleeding disorders, there are very few case reports describing an anesthetic method 
for vWD patients (Hara et at., 2009; Caliezi et al., 1998; Jones et al., 1999; Milaskiewicz et al., 
1990; Cohen et al., 1989). Paucity of large case series showing that epidural interventions are 
safe makes anesthetists hesitate when conducting anesthesia on women with vWD.  
When the vWF activity becomes >50 IU.dl-1 in women with vWD Type 1 or this value is 
reached through replacement, an epidural anesthesia can safely be administered. However, 
the decision of using an epidural anesthesia should be made jointly by an experienced 
anesthetist, a hematologist and a gynecologist (Lee et al., 2006). Epidural anesthesia is not 
recommended for patients with vWD Type 2 and 3 (Pasi et al., 2004). An epidural anesthesia 
should be administered by an experienced anesthetist. 
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2.3.1.3 Factor V deficiency 
Factor V deficiency is a congenital bleeding disorder which prevails very rarely (1 in 
1000000) in the population (Asselta et al., 2006). Factor V itinerates as an inactive cofactor 
in the plasma and is activated by thrombin. Activated factor V works as a cofactor with 
factor VIIIa and factor Xa to convert prothrombin into thrombin (Fogerty & Connors, 
2009).  
Factor V deficiency is classified as quantitative (type 1) and qualitative (type II) (Asselta et 
al., 2006). When the plasma FV antigen level becomes <15%, it is classified as a serious Type 
I deficiency and when it becomes <60-65%, as a moderate Type I deficiency. A moderate to 
serious level of bleeding occurs in serious Type I deficiency (Asselta et al., 2006; Vellinga et 
al., 2006).  
There is no evident information on the use of neuraxial techniques in these patients. 
However, it was reported that the neuraxial techniques were safe in labor epidural analgesia 
when the FV level becomes > 60% (Le Gouez et al., 2011). In pregnancy, prothrombin time 
(PT) can be normal although the FV level is low (Cerneca et al., 1997). For this reason, PT 
alone is not sufficient in determining the FV level. The FV level should be reassessed to be 
able to remove the epidural catheter safely (Kadir et al., 2009).  
2.3.1.4 Inherited hemorrhagic telangiectasia  
Hereditary hemorrhagic telangiectasia (HHT), also known as the Osler-Weber-Rendu 
Syndrome, is a congenital autosomal dominant multiple vascular dysplasia which is seen in 
1 person out of 5000-8000 (Begbie et al., 2003). This disease is characterized by multiple 
arteriovenous malformations (AVMs) associated with the lack of capillaries joining arteries 
with veins in the solid organs of a body and telangiectasis of cutaneous and mucous 
membranes (Hereditary Hemorrhagic Telangiectasia Foundation International Inc., 2007). 
Vascular dysplasia is mostly seen in pulmonary, cerebral, gastrointestinal and spinal 
vascular structures. The course of the disease may progress silently or in a life-threatening 
manner from a high-output heart failure secondary to arteriovenous shunting, a systemic 
emboli, rupture of AVMs up to a fatal hemorrhage (Lomax & Edgcombe, 2009).  
A successful anesthesia can be administered to patients with HHT only if the existing 
specific AVMs are known, cardiovascular instability is avoided and a prophylaxis is applied 
for systemic emboli that may develop as a result of AVM shunting. Spinal AVMs constitute 
a relative contraindication for regional techniques (Lomax & Edgcombe, 2009).  
2.3.1.5 Inherited disorders of platelet dysfunctions  
2.3.1.5.1 Glanzmann’s thrombasthenia 
Glanzmann’s Thrombasthenia a congenital, hereditary and hemorrhagic disorder caused by 
qualitative and quantitative impairment of platelet glycoprotein (GP) IIb/IIIa. Bleeding such 
as purpura, epistaxis, gingival hemorrhage and menorrhagia are seen in these patients due 
to defective platelets in the formation of hemostatic clump. The disorder can clinically be 
diagnosed through the signs of normal number of platelets, abnormal platelet aggregation 
and prolonged bleeding time (George et al., 1990). 
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2.3.1.5.2 Bernard-Soulier syndrome 
Bernard-Soulier syndrome is a rarely seen bleeding disorder inherited in an autosomal 
recessive way. This disease develops in connection with the abnormality or lack of platelet 
membrane glycoprotein GPIb-V-IX and it is characterized by giant platelets, 
thrombocytopenia in various grades and prolonged bleeding time (Kostopanagiotou et al., 
2004). Clinically it progresses with excessive bleeding not proportionate to the degree of 
thrombocytopenia and the bleedings are fatal (Bernard, 1983).  
2.3.1.6 Inherited thrombophilia 
2.3.1.6.1 Protein C deficiency  
Protein C deficiency is a thrombotic disease inherited in an autosomal dominant way with a 
prevalence of 0.2-0.5% in the population (Aiach et al., 1997; Reitsma, 1997; Walker, 1997). 
Protein C is the central protein of the major antithrombotic system of hemostasis. Protein C 
itinerates in the plasma as an inactive zymogen linked to vitamin K. It is activated in 
endothelium by the thrombomodulin-thrombin complex. Activated Protein C inactivates 
coagulation factor Va and VIIIa. It also has a fibrinolysis function by neutralizing inhibitor 
of tissue-type plasminogen activator (TPAI) (Esmon, 1989). 
Protein C deficiency is at increased risk for deep vein thrombosis and pulmonary embolism, 
especially during pregnancy and the post partum period. For this reason patients are 
administered thromboemboli propylaxis and thrombosis therapy during preoperative and 
postoperative periods. Continuation of anticoagulation therapy, on the other hand, may 
increase the risk of re-bleeding with life-threatening mass effect (Ranasinghe et al., 2008; 
Sternberg et al., 1991). It is important to discuss a benefit-loss balance for these patients 
before a neuraxial procedure.  
2.3.1.6.2 Antithrombin III deficiency 
Antithrombin III deficiency is a hereditary disorder received in an autosomal dominant way 
and is seen in the population at a rate between 1/2000 and 1/5000 (Rosenberg, 1975). It is a 
glycoprotein which inhibits factor IIa (thrombin) and antithrombin factor Xa. Antithrombin 
deficiency is of the highest clinical significance among the congenital thrombophilia as it 
causes life-threatening thromboses (Maclean & Tait, 2007). A long-lasting anticoagulant 
therapy becomes inevitable in these patients due to a recurring venous thromboemboli 
(VTE) risk. A prophylactic anticoagulation should be administered to asymptomatic 
individuals especially in high-risk episodes (e.g. surgery, immobility and pregnancy) 
(Birnbach & Grunebaum, 1991).  
LMWH is particularly recommended as an anticoagulant treatment of antithrombin 
deficiency. The use of LMWH is restricted in regional anesthesia due to the risk of bleeding. 
The American Society of Regional Anesthesia (ASRA) guidelines today recommends to 
discontinue the treatment at least 24 h before any neuraxial procedure is initiated (if the 
treatment is used in the right intensity) (Horlocker et al., 2003 ). This period of discontinued 
anticoagulant treatment in patients with high risk of VTE constitute a critical interval. In the 
last ten years, the use of antithrombin concentrations is recommended in high-risk situations 
(e.g. cesarean section, elective surgery and delivery) (Tiede et al., 2008). There are a limited 
number of case reports stating successful administration of epidural anesthesia and 
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analgesia under an antithrombin treatment in hereditary antithrombin deficiency (Pamnani 
et al., 2010). 
2.3.2 Acquired coagulation defects 
2.3.2.1 Vitamin K deficiency  
Patients with vitamin K deficiency should be given oral or parenteral treatment depending 
on the reason of the deficiency. In a vitamin K deficiency, only the prothrombin time (PTT) 
is prolonged. Vitamin K deficiency is extremely common among hospitalized patients for 
multiple reasons. Poor diet (lack of leafy vegetables) often results in hospitalization. 
Warfarin is a competitive inhibitor of vitamin K. The amount of vitamin K required to 
reverse its effect depends on the amount of warfarin in blood.  
2.3.2.2 Drug-associated hemorrhage 
Drug-associated hemorrhage may stem from heparin, vitamin K antagonists, platelet 
aggregation inhibitors, glycoprotein IIb/IIIa inhibitors or direct thrombin inhibitors. 
Regional anesthesia in the presence of anticoagulation  
a. Anesthetists should be aware of the potential risk of bleeding when conducting regional 
anesthesia techniques in patients who receive antithrombotic treatment and are planned 
to undergo a surgery. When a potent antithrombotic drug was involved, this often has 
resulted in avoidance of regional anesthesia techniques due to the concern about the 
patient’s safety. Therefore, some national anesthesia societies have published guidelines 
describing how to safely conduct regional anesthesia when using antiplatelet, 
anticoagulant and thrombolytic medication. The first national recommendations on 
neuraxial anesthesia and antithrombotic drugs were published by the German Society for 
Anesthesiology and Intensive Care in 1997 (Gogarten et al., 1997), followed by the 
American Society of Regional Anesthesia (ASRA) in 1998 (Horlocker & Wedel, 1998), and 
Belgian anesthesiologists in 2000 (Belgian Guidelines 2000). In this context, there are a 
large number of recommendations approved by scientific anesthesia societies (Horlocker 
et al., 2003; Llau et al., 2005; Vandermeulen et al., 2005; Samama et al., 2002). This enabled 
comparison of similarities and differences in some important situations (Llau et al., 2007). 
The European Society of Anesthesiology (ESA) has recently published recommendations 
about the time intervals between the neuraxial blockage and removal of the catheter and the 
administration of an anticoagulant when anticoagulant agents are being used (Gogarten et 
al., 2010). Such guidelines are continuously being updated because new anticoagulants are 
regularly being developed and they are based on large case series, case reports and 
pharmacologic data of anticoagulant drugs rather than controlled studies.  
Administrators of neuraxial block on patients receiving antithrombotic treatment should be 
weary of possible hematoma formation resulting into neurologic deficit. Epidural hematoma 
related to neuraxial anesthesia is a rare but potentially devastating complication (Guffey et al., 
2010; Li et al., 2010; Han et al., 2010). The risk of hemorrhage is lowest in spinal anesthesia, 
which employs fine needles, and highest in epidural catheter anesthesia, which requires the 
largest needle gauges available. Nearly half of all cases of bleeding occur during the removal 
of an epidural catheter, and this procedure must be regarded as critical as catheter insertion 
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(Vandermeulen et al., 1994). Catheter manipulation and removal carry similar risks to 
insertion, and the same criteria should apply. Appropriate neurological monitoring is essential 
during the postoperative recovery period and following catheter removal. 
b.  Antithrombotic drugs and Regional Anesthesia  
This is used if it is believed to be more beneficial than the alternative methods. 
Anticoagulants, antiplatelet drugs and thrombolytics are used for the prevention and 
treatment of stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism 
in many patients undergoing surgery (Table 4). (Donegan et al., 2007). The risk of 
developing epidural hematoma is reduced if care is taken for the characteristics of these 
drugs and the safe time intervals needed for administering the regional technique (Llau et 
al., 2001). Neuraxial anesthesia can be accepted in these patients only if coagulation is 
optimized and monitoring is done during the application. 
 
Drugs groups  
Heparins 
Anti- Xa agents 
Direct thrombin inhibitors 




Table 4. Antithrombotic drugs 
Regional anesthesia in patients on treatment with unfractionated heparins 
Factor IIa produces an anticoagulant effect by inhibiting the antithrombin III enzyme 
activity on IXa and Xa (Weitz, 1997; Hirsh & Raschke, 2004). Unfractional heparin (UH) is 
administered subcutaneously (sc) or intravenously (iv). Its half-life varies according to the 
dose (Llau et al., 2007).   
Coagulation tests need not be done for patients who receive sc UH in prophylactic doses 
(<15000IU/day) However, a thrombocyte count should be carried out in patients who have 
received treatment for more than 5 days and for whom there is a need to distinguish 
heparin-induced thrombocytopenia. The treatment should be suspended 2 to 4h before 
removing the catheter. The next heparin dose should be postponed until 1h after the 
procedure (Gogarten et al., 2010). 
Although the UH dose used in venous thromboprophylaxis is safe, the risk of bleeding 
increases in therapeutic doses. For this reason, insertion and removal of catheters is 
contraindicating in patients receiving therapeutic treatment. If a safe removal of neuraxial 
blockage or catheter is planned, administration of intravenous (iv) heparin should be 
suspended for at least 4h and it should be ascertained before the procedure that aPTT, 
activated clotting time (ACT), anti-Xa activity and thrombocyte quantity are all normal. It 
should be avoided for 2h in low doses if an intraoperative heparinization is planned and for 
6-12 hours if a full heparinization is planned (Gogarten et al., 2010).   
Regional anesthesia in patients on treatment with low molecular weight heparins 
This is widely used to prevent and treat deep vein thrombosis (DVT) by inhibiting factor Xa 
formation. It became superior to the other anticoagulants as it has high level of bioavailability, 
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the risk of bleeding is low and it can easily be used without any need for monitoring blood 
clotting (Vandermeulen, 2010). LMWH reaches the peak plasma level approximately 4h after a 
subcutaneous procedure and its activity continues for 24h (Hirsh et al., 2001).  
In order to avoid any bleeding complication, there must be at least 12h (in prophylactic dose 
of LMWH) or 24h (in therapeutic dose of LMWH) between the last dose of LMWH and the 
removal of the neuraxial blockage or epidural catheter (Vandermeulen et al., 1994; Bergqvist 
et al., 1993). The next LMWH dose should be applied 4h after the epidural/spinal puncture 
or catheter removal (Gogarten et al., 2010). The probability of developing a heparin-induced 
thrombocytopenia (HIT) after LMWH is ten times less as compared to UH (Warkentin et al., 
1995). 
However, a thrombocyte count is recommended after using LMWH for more than 5 days 
(Vandermeulen, 2010). 
Danaparoid 
Danaparoid is a glycosaminoglycan containing 84% heparan sulphate, 12% dermatan 
sulphate and 4% chondroitin sulphate. Its anti-thrombotic effect occurs through 
antithrombin-induced inhibition of factor Xa (Ibbotson & Perry, 2002). Coagulation is 
monitored by using only the anti-X activity. It is used as an alternative to UH and LMWH in 
prevention and treatment of pulmonary emboli and VTE in patients with a history of 
danaparoid HIT (Wilde & Markham, 1997). Since it has a 22-hour elimination half-life, a 
preoperative danaparoid administration should be avoided in patients who are planned to 
undergo a neuraxial blockage (Gogarten et al., 2010).  
Regional anesthesia in patients on treatment with factor Xa inhibitors 
Fondaparinux 
Fondaparinux is a selective reversible inhibitor of coagulation factor Xa. It has a high affinity 
with antithrombin III without affecting active thrombin and platelet aggregation (Weitz et 
al., 2004). 
A single dose of it is used daily because the half-life of this compound is 18-21h (Boneu et 
al., 1995). The safe interval between a fondaparinux application and a single-shot neuraxial 
anesthesia is 6h. The catheter can be removed 36h after the last dose. A Fondaparinux dose 
should be given at least 12 hours after removing the catheter (Llau Pitarch et al., 2005).  
Rivaroxaban 
Rivaroxaban is a selective factor Xa inhibitor. It is currently administered orally as a single 
dose of 10 mg to prevent a deep vein thrombosis following a total hip and knee prosthesis 
surgery. It reaches a maximum plasma level in 2-4h. APTT is prolonged depending on the 
dose. It prolongs PT with a close correlation with the plasma concentration (Kubitza et al., 
2005). A time interval of 22-26h is required between the last dose of rivaroxaban and 
removal of the neuraxial catheter (Gogarten et al., 2010). The next dose of rivaroxaban 
should be applied 4-6 h after the catheter is removed (Gogarten et al., 2010).  
Apixaban 
Apixaban is an oral, reversible, rivaroxaban-linked direct inhibitor of factor Xa. Its half-life is 
between 10-15 h (Weitz et al., 2008). There must be a time interval of 26-30h between the last 
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dose of apixaban (2.5mg) and catheter removal. Its next dose should be given 4-6 hours after 
catheter removal (Gogarten et al., 2010).  
Regional anesthesia in patients treated with direct thrombin inhibitors 
This group of drugs uses direct selective thrombin inhibition to produce both perioperative 
thromboprophylaxis and therapeutic anticoagulation. They also inactivate thrombin-linked 
fibrin and prevent thrombus from further growing (Gogarten et al., 2010). Their 
anticoagulant effects can be monitored using aPTT and ecarin clotting time (ECT) 
(Greinacher, 2004). 
Hirudins: bivalirudin, desirudin and lepirudin 
All hirudins are potent anticoagulants and bind thrombin irreversibly. They can be used 
in HIT patients because they do not interact with thrombocyte factors (Lubenow & 
Greinacher, 2002). Lepirudin and desirudin have a half-life of 1.3-2 h and bivalirudin 25-
30 min (Robson et al., 2002; Dasgupta et al., 2000). In patients with normal renal function, 
there must be at least 8-10 h of time between the last dose of a hirudin and insertion of a 
neuraxial blockage / catheter or removal of the catheter. The next dose may be given 2-4 h 
after catheter removal. 
Argatroban 
Argatroban is a reversible direct thrombin inhibitor (Kaplan, 2003; Kathiresan et al., 2002). 
Its half-life is 35-45 min (Yeh & Jang, 2006). It is applied intravenously 0.5-2 µkg/min in 
patients with normal organ functions and it prolongs aPTT about 1.5 to 3 times that of the 
normal. There must be at least 4 h of time between the last dose of argatroban and insertion 
or removal of a neuraxial blockage / catheter. The next dose may be given 2 h after catheter 
removal. 
Dabigatran 
Dabigatran oral is a reversible thrombin inhibitor which is used for VTE prophylaxis (Weitz 
et al., 2008). It is used every other day because it has a long half-life (12-17 h). The first dose 
of dabigatran is applied 4 h postoperatively. There must be 4 h between its last dose and 
catheter removal. The next dabigatran dose can be given 2 h after catheter removal 
(Boehringer-Ingelheim, 2009). 
Regional anesthesia in patients treated with Vit K Antagonists 
Neuraxial block is definitely contraindicated in patients treated with Vit K antagonists such 
as acenocoumarol, phenprocoumon and warfarin. All of these drugs cause coagulation 
factor II, VII, IX and X deficiencies and protein C and S inhibitions (Ansell et al., 2004). A 
few days after discontinuation of these drugs, coagulation returns to normal; the progress 
can be controlled by using the international normalized ratio (INR). Vit K antagonists are 
discontinued 3-5 days prior to the administration of regional technique in the preoperative 
period and one of the other anticoagulants, particularly LMWH, is temporarily 
administered to the patient (Dunn & Turpie 2003). INR should be <1.4 before the regional 
technique. If the epidural catheter needs to be removed under a warfarin therapy, it should 
be removed before the anticoagulant effect begins (INR<1.4) (Llau Pitarch et al., 2005).  
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Regional anesthesia in patients on treatment with antiplatelet drugs 
Antiplatelet agents are compounds used for preventing arterial thrombosis in various 
clinical processes (Samama et al., 2002; Tufano et al., 2002). They inhibit platelet functions 
and are classified according to their mechanisms of action: 
Acetylsalicylic acid (ASA) 
ASA shows its effect by irreversibly inhibiting the cyclooxygenase enzyme. Its time of action 
is as long as a platelet life (7-10 days) (Vandermeulen, 2010). The bleeding effect of ASA 
depends on its dose (Serebruany et al., 2005). It inhibits generation of thromboxane A2 in 
low doses and prostacyclin in high doses. It was shown that the risk of spontaneous 
bleeding was quite low in patients having normal quantity of platelets who use low doses of 
ASA during an anti platelet treatment (McQuaid & Laine, 2006). When ASA or non-steroidal 
anti-inflammatory drugs (NSAIDS) are used alone, the risk of a spinal/epidural hematoma 
does not increase and they do not constitute a contraindication in using regional techniques. 
A limited number of studies in the literature demonstrate that spinal hematoma does not 
pose and extra risk in this group of patients CLASP (Collaborative Low-dose Aspirin Study 
in Pregnancy) (Collaborative Group., 1994; Horlocker et al., 1995; Horlocker et al., 2002). 
It was shown that a postoperative thromboprophylaxis was more beneficial than a 
preoperative one (Hull et al., 2000). 
For this reason, it is recommended to administer a VTE prophylaxis involving ASA in the 
postoperative period following the regional technique (Llau et al., 2005).  
The suggestion that the use of ASA should be discontinued 7 days before the operation in 
patients getting ready for an operation is outstanding among other recommendations (Kövesi 
& Royston, 2002). Having a break for 7 days will increase the risk of developing cardiovascular 
and neurologic complication (Burger et al., 2005). It is recommended that antiaggregants, ASA 
in particular, should be restarted between postoperative 6 and 24 h (Llau et al., 2007).   
Thienopyridines 
Thienopyridines which consist of ticlopidine and clopidogrel show their effect by 
antagonizing adenosine diphosphate (ADP) in the purine receptors of thrombocytes. These 
drugs reach their peek activity 3-5 days after having been received and their antiaggregant 
effect extents up to 7-10 days (Patrono et al., 2004). The half-life of ticlopidine is 30-50 h and 
that of clopidogrel is 120 h (Vandermeulen, 2010). Thienopyridines have a very large 
antiaggregant capacity. There is no data indicating that they are being safely used in 
regional techniques. However, there are reports notifying development of a spinal epidural 
hematoma following the neuraxial block in a clopidogrel therapy (Litz et al., 2004). Today, it 
is not recommended to administer a regional technique to patients who are under the 
influence of ticlopidine or clopidogrel. Nevertheless, a regional technique can safely be 
administered after suspending the clopidogrel therapy for 7 days and the ticlopidine 
therapy for 10 days (Llau et al., 2007).   
GP IIb/IIIa receptor antagonists 
GPIIb/IIIa receptor antagonists which consist of abciximab, tirofiban and eptifibatide are 
among the most effective drugs today for inhibition of platelet aggregation. They show their 
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effect by reversibly inhibiting glycoprotein IIb/IIIa receptors of platelets. They are mostly 
used in treating acute coronary syndrome. After being applied, eptifibatide/tirofiban is 
effective for 8-10 h and abciximab for 24-48. A thrombocytopenia may develop within 1 to 
24 hours after they are administered (Dasgupta et al., 2000; Huang & Hong, 2004). Use of a 
regional technique or removal of catheter can be done 8 h after the last dose of 
eptifibatide/tirofiban or 24-48 h after the last dose of abciximab (Gogarten, 2006). A 
thrombocyte count should however be done to confirm that there is no thrombocytopenia 
(Llau et al., 2007). Safe time interval before and after a neuraxial block in patients receiving 
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* When ASA is given as a single drug, neuraxial block could be performed freely 
Table 5. Safe time interval before and after a neuraxial block in patients receiving 
antithrombotic drugs  
2.3.2.3 Disseminated intravascular coagulation (DIC)  
The magnitude of a trauma may be accompanied by a coagulation change. Specific injuries 
such as impairment of the central nervous system, bone fractures and amniotic fluid emboli 
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are often accompanied by disseminated intravascular coagulation (DIC) (Levi & Ten, 1993). 
The embolized material gains strength with thromboplastin and causes intravascular 
coagulation as the direct clotting factors are consumed (Hess & Lawson, 2006). 
In patients with DIC following an acute trauma, the level of fibrinogen usually goes down 
first. This drop in fibrinogen is followed by consumption of other coagulation factors. The 
prothrombin time (PTT) and the active partial thromboplastin time (aPTT) are prolonged 
and the number of platelets and the level of fibrinogen drop (Gando et al., 1992; Ordog et al., 
1985). 
In patients with post-traumatic DIC, a distinct drop in the levels of protein C and 
antithrombin indicates an anticoagulant activity deficiency (Gando, 2001; Gando et al.,1988; 
Gando et al., 1992; Chesebroet al., 2009). 
DIC divides into two phenomena, fibrinolitic (hemorrhagic) and antifibrinolitic 
(thrombotic). DIC has the character of a fibrinolitic phenomenon in the early stage of the 
trauma, that is, after approximately 24-48 h and is accompanied by massive hemorrhages 
(Sawamura et al., 2009). DIC becomes a thrombotic phenomenon in the later stage of the 
trauma, that is, after approximately 3-5 days. It is then characterized by a development of 
multiorgan dysfunction (MODS) (Gando, 2001).  
2.3.2.4 The coagulopathy of massive trauma 
In patients with serious trauma, coagulopathy is associated with the loss, consumption and 
dysfunction of coagulation factors. Coagulopathy is aggravated by hemodilution, acidosis 
and hypothermia (Armand & Hess, 2003). 
Hemodilution occurs due to a massive blood loss. A massive bleeding causes a decrease in 
the number of platelets, shortening of coagulation time, an increase in fibrinogen turnover 
and consumption of coagulation factors (Turpini & Stefanini, 1959). Moreover, the liquid 
and blood products and massive transfusion of hypovolemia result in a dilution which 
intensifies the coagulopathy (Armand & Hess, 2003). 
Acidosis occurs as a result of tissue hypoperfusion and hypoxia associated with a shock. 
When pH becomes <7.1, the propagation stage of thrombosis comes to be blocked (Martini, 
2009).  
A serious hypothermia decreases coagulation enzyme activity and impairs platelet functions 
(Martini, 2009; Wolberg et al., 2004). 
2.3.2.5 Idiopathic thrombocytopenic purpura (ITP) 
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune thrombocytopenic 
coagulopathy, which is seen in 1 person out of 100000. It is characterized by a persistent 
thrombocytopenia which develops as a result of destruction of platelets by the 
reticuloendothelial system due to antibodies that adhere to thrombocytes (Kessler et al., 
1982). Platelets have an important role in continuation of coagulation cascade in the 
hemostatic system and in formation of hemostatic clumps (Beilin et al., 1997). A low number 
of platelets impairs surgical hemostasis by increasing the risk of hemorrhage and may cause 
anesthetic complications such as hematoma (Chow et al., 2011). Patients with ITP should be 
distinguished from the other causes of thrombocytopenia including sepsis, pregnancy-
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induced hypertension, disseminated intravascular coagulation, drug-induced 
thrombocytopenia, thrombocytopenia associated with autoimmune diseases (systemic lupus 
erythematosus, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and 
hereditary forms of thrombocytopenia) (Webert et al., 2003).   
The number of platelets helps distinguish the other diseases involving coagulopathy in 
clinical settings.  
In patients with ITP, platelet functions are normal, and the number of platelets is low and 
stable (Abramovitz &Beilin,2003). 
In assessing platelet functions of ITP patients, the bedside tests of bleeding time and 
thromboelastography as well as platelet function analysis tests (aggregometry or flow 
cytometry) can be used (Beilin et al., 1997).  
Traditionally, regional anesthesia is believed to be contraindicating in thrombocytopenia. 
What lies behind this belief is that the absolute cut-off point of platelets was accepted to be 
100.000/mm-3 because the bleeding time was prolonged when the number of platelets went 
below 100.000/mm-3. Following the belief that a neuraxial anesthesia is not safe below the 
absolute platelet number, many clinicians avoid carrying out any epidural procedures 
(Harker & Slichter, 1972; Bromage, 1993). Many textbooks and articles of our time suggest 
that epidural applications can be done safely at <100.000/mm-3 (Beilin et al., 1997; Rasmus et 
al., 1989; Rolbin et al., 1988; British Committee for Standards in Haematology General 
Haematology Task Force, 2003). Most of the anesthetists believe that epidural anesthesia is 
not contraindicating in clinical practice within the interval of 80-100x10-3mm-3 (Stamer et al., 
2007; Beilin et al., 1997; Van Veen et al., 2010).  
Safe administration of epidural techniques to thrombocytopenic patients depends not only on 
the absolute platelet number but also on the reason underlying the thrombocytopenia, the rate 
at which the number of platelets decrease and the presence of a coagulopathy (Douglas & 
Ballem, 2008; Kam et al., 2004). Presence of coagulopathy contraindicates the use of regional 
anesthesia. However, a neuraxial block can be used in thrombocytopenic patients when their 
platelet quantity is adequate and stable, platelet functions are normal and there is no clinical 
evidence of a coagulopathy (Van Veen et al., 2010). The anesthetist should decide on a regional 
anesthesia on such patients after assessing the risks and benefits involved.  
Since there is the risk of developing epidural hematoma in thrombocytopenic patients when 
either inserting or removing an epidural catheter, it is necessary to check the number of 
platelets before the procedure. The epidural catheter should be removed at the earliest 
opportunity when clinical data verifies that there is no coagulopathy involved (Douglas, 2001). 
2.4 Patient refusal 
A face-to-face interview should be held with the patient and the benefit-loss balance of the 
intended method should be explained. The procedure should not be attempted before 
obtaining the patient’s consent. 
In regional anesthesia patient cooperation is required to a certain extent. Achieving this may 
be difficult or even impossible in patients with dementia, psychosis or emotional 
dysregulation (Morgan et al., 2008).  
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2.5 Hemodynamic instability 
The observable cardiovascular effect of an epidural anesthesia is complex and variable, and 
it is associated with a number of factors. The magnitude of sympathetic denervation, 
balance of sympathetic and parasympathetic activities, pharmacological effect of 
systemically absorbed local anesthetics, adrenalin content of anesthetic solutions, blood 
distribution associated with cardiac filling and cardiovascular functions of patients all play a 
role in the circulatory effect of an epidural anesthesia (Veering & Cousins, 2000).  
The cardiovascular response of an epidural anesthesia depends not only on the somatic, 
sensory and blocked motor fibres but also on the decrease in preganglionic sympathetic 
tone. Local anesthetics administered to the epidural area pass into the systemic circulation 
by being absorbed through a local perfusion and cause a blockage of the sympathetic system 
(Hickey et al., 1986; Shimoji et al., 1987).  
The individual cardiovascular response to the sympathetic blockage differs according to the 
pre-blockage degree of sympathetic tones (Veering & Cousins, 2000). Clinical use of 
epidural anesthesia is limited due to its risk of aggravating a preexisting systemic 
hypotension.    
2.6 Increased intracranial pressure 
Intracranial pressure (ICP) changes are characterized by the change of complains in the 
intracranial compartment. There is a close relationship between intracranial volume changes 
and ICP. When complains decrease, intracranial content increases. When ICP increases, 
blood flow to the brain decreases and the cerebral perfusion pressure declines (Adams & 
Rapper,1997).  
The effect of lumbar epidural anethesia on intracranial pressure (ICP) has been studied both 
in animals (Bengis & Guyton, 1977)and humans (Usubiaga et al., 1967). It is known that 
epidural injections, at least transiently, increase ICP. With the increase in ICP, the elastance 
and resistance of the epidural area also increase (Grocott & Mutch, 1996). Intracranial 
hypertension has long been considered a contraindication to epidural anesthesia. 
2.7 Local or systemic infection  
The latest structural and functional studies showed that there is a firm interaction between 
inflammation, coagulation and fibrinolytic system (Esmon, 2003). Inflammation initiates 
clotting, impairs fibrinolytic system and decreases the activity of natural anticoagulant 
mechanisms. When inflammation starts as a local infection, coagulation activation begins as 
a host response to prevent propagation of microorganisms in the systemic circulation. Only 
in patients with very severe infection, the systemic coagulation system is activated when 
inflammatory cytokines disseminate in the circulation (Chrousos, 1995; Harris BH & 
Gelfand, 1995). 
It is still controversial to use neuraxial anesthesia in patients with sepsis and systemic 
inflammatory response syndrome (SIRS) due to the concern that it might worsen 
hemodynamic instability and trigger potential problems. Active protein C therapy can be 
used in treating patients with serious sepsis. Insertion of an epidural catheter is 
contraindicated in patients with serious sepsis who are undergoing an active protein C 
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therapy (Horlocker et al., 2003). Use of an epidural catheter in these patients will not only 
expose them to a higher risk but will also prevent the use of APC which would improve the 
patient’s treatment (Gibson &Terblanche, 2011).  
2.8 Pre-existing neurological diseases 
It has been controversial in the past and also in our time to use neuraxial blocks in patients 
with a neuromuscular disease (Schmitt et al., 2004; Al-Nasser, 2002). Neuraxial blocks are 
hesitantly used because there is not a unique guideline for these diseases, the published data 
contradict each other and local anesthetics involve a potential risk of neurotoxicity (Martucci 
et al., 2011; Dolmass et al., 2003). 
The symptoms may worsen after the block in patients who previously had a neurologic 
deficit or a demyelinating disease. It is impossible to differentiate whether such condition 
resulted from the complications developed after the block or the exacerbation of the existing 
disease. Some clinicians oppose, for this reason, to use neuraxial blocks in such patients 
(Morgan et al., 2008).  
The basic problem is the lack of controlled studies to assess the potential risk that may 
increase in various neurologic diseases after a neuraxial application. There is also a theoretic 
risk of some complications (local anesthetic toxicity, nerve damage, hemorrhage and 
infection) which develop secondary to a regional anesthesia in this specific group of 
patients. However, there are a limited number of case reports showing that regional 
anesthesia is not accompanied by the underlying aggravation (Pogson et al., 2000; Stoelting 
& Dierdorf, 2002). 
A neuraxial blockage may be preferred after a detailed discussion of the individual disease 
is made without overlooking the risk of worsening the neurologic function. 
3. Conclusion  
Anesthesia societies, in patient with coagulation defect and anticoagulant agents uses, 
developed guidelines to help anesthesiologists to predict the optimal time for neuraxial 
techniques. These guidelines based on clinical experinces and case series. The most basic 
common features of these guidelines are the nontraumatic implementation of the neuraxial 
analgesia by experienced anesthesiologists. Of course the management of individual risks 
and benefits must perform carefully. 
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(anesthesia) and a loss of pain (analgesia), by reversibly interrupting the transmission of signals through
nerves in or near the spinal cord. This form of pain relief has been found useful in many clinical situations. This
book intends to provide an in-depth review of the current knowledge on epidural analgesia. The use of this
form of analgesia is explored by contributors from different perspectives, including labor and delivery,
postoperative analgesia in both pediatric and geriatric patients, and its role during anesthesia and surgery. In
order to provide a balanced medical view this book was edited by an obstetric anesthesiologist.
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